Back to School: How biopharma can reboot drug development. Access exclusive analysis here

JX-594: Phase I/II data

In an open-label, Korean Phase I/II trial in 13 evaluable patients,

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE